Leap Therapeutics, Inc. (LPTX)
Market Cap | 64.67M |
Revenue (ttm) | n/a |
Net Income (ttm) | -53.37M |
Shares Out | 38.26M |
EPS (ttm) | -2.13 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 160,122 |
Open | 1.860 |
Previous Close | 1.870 |
Day's Range | 1.680 - 1.870 |
52-Week Range | 1.235 - 5.000 |
Beta | 0.42 |
Analysts | Strong Buy |
Price Target | 10.40 (+515.39%) |
Earnings Date | Aug 12, 2024 |
About LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LPTX stock is "Strong Buy." The 12-month stock price forecast is $10.4, which is an increase of 515.39% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/v/h/press1-2426501.jpg)
Leap Therapeutics Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...
![](https://cdn.snapi.dev/images/v1/2/k/press14-2367151.jpg)
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and developme...
![](https://cdn.snapi.dev/images/v1/h/z/press2-2328451.jpg)
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...
![](https://cdn.snapi.dev/images/v1/l/a/conf12-2231640.jpg)
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rec...
![](https://cdn.snapi.dev/images/v1/h/z/press8-2214361.jpg)
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dou...
![](https://cdn.snapi.dev/images/v1/z/s/press11-2212917.jpg)
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enr...
![](https://cdn.snapi.dev/images/v1/t/9/conf7-2191856.jpg)
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
CAMBRIDGE, Mass. , Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that th...
![](https://cdn.snapi.dev/images/v1/c/h/press7-2166797.jpg)
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...
![](https://cdn.snapi.dev/images/v1/w/d/press20-2154204.jpg)
Leap Therapeutics Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...
![](https://cdn.snapi.dev/images/v1/g/1/conf1-2048911.jpg)
Leap Therapeutics to Participate at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...
![](https://cdn.snapi.dev/images/v1/q/w/press9-2021204.jpg)
Leap Therapeutics Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...
![](https://cdn.snapi.dev/images/v1/h/r/press5-1967603.jpg)
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ba...
![](https://cdn.snapi.dev/images/v1/w/w/press16-1941002.jpg)
Leap Therapeutics Announces Reverse Stock Split
CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it...
![](https://cdn.snapi.dev/images/v1/q/l/conf18-1908671.jpg)
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overal...
![](https://cdn.snapi.dev/images/v1/l/c/press13-1889600.jpg)
Leap Therapeutics Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...
![](https://cdn.snapi.dev/images/v1/z/o/press14-1833773.jpg)
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
CAMBRIDGE, Mass. , April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...
![](https://cdn.snapi.dev/images/v1/g/a/press14-1811134.jpg)
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...
![](https://cdn.snapi.dev/images/v1/i/c/press3-1801006.jpg)
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotec...
![](https://cdn.snapi.dev/images/v1/p/r/press14-1730167.jpg)
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights...
![](https://cdn.snapi.dev/images/v1/t/v/press7-1721101.jpg)
LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap sh...
![](https://cdn.snapi.dev/images/v1/e/k/press20-1715183.jpg)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating Leap Therapeutics, Inc. ("Leap") (NASDAQ: LPTX) regarding possible breaches of fiduciary duties and oth...
![](https://cdn.snapi.dev/images/v1/u/l/press20-1713758.jpg)
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Leap Therapeutics, Inc. - LPTX
NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...
![](https://cdn.snapi.dev/images/v1/g/r/press20-1713694.jpg)
SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.
NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. ("Leap" or the ...
![](https://cdn.snapi.dev/images/v1/x/i/press16-1710377.jpg)
Leap Therapeutics Acquires Flame Biosciences
Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-f...
![](https://cdn.snapi.dev/images/v1/f/2/conf17-1703885.jpg)
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
CAMBRIDGE, Mass. , Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that D...